Project Grant R01HL182777
- Federal Project Grant Summary Northwestern University received a $654,762 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 1, 2026, with completion targeted for February 28, 2031. The grant funds research investigating regulatory T cell (Treg) mechanisms that limit persistent inflammation during recovery from viral pneumonia. The research addresses a critical public health challenge, as viral...
- Federal Project Grant Award Summary Northwestern University's Sponsored Research Division received a $1.597 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 1, 2026, with completion targeted for December 31, 2027. The research project, conducted in Chicago, Illinois, investigates mechanisms to improve cardiac allograft survival in heart transplant recipients by modulating...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $684,570 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 1, 2026, with a completion date of April 30, 2030. The project delivers translational research and development of a bioengineered mitochondrial therapy platform designed to address endothelial injury in vascular surgery. The research platform...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Trustees of Columbia University in the City of New York $1,537,970 under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 1, 2025, with a completion date of March 14, 2026. This Project Grant supports mechanistic research investigating posttranscriptional RNA modifications in lung development and regeneration, specifically examining how the METTL3/14...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division has received a $1.466 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, through June 30, 2030. The award funds a comprehensive research initiative to characterize apolipoprotein proteoforms and their relationships with cardiometabolic health and coronary heart disease events. The research...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $2.23 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for May 31, 2029. The research, conducted in Chicago, Illinois, investigates vascular proliferative resilience—specifically the mechanisms by which endothelial cells in large arteries, particularly...
- Federal Project Grant Award Summary Award Details: The National Heart, Lung, and Blood Institute (NHLBI) awarded a $170,570 Project Grant to Brigham and Women's Hospital (Department of Faulkner Pathology) effective April 1, 2026, through March 31, 2028, under CFDA 93.837 (Cardiovascular Diseases Research). The award supports investigator Dr. Rinku Sharma's research into the molecular mechanisms underlying lung function decline and aging. Research Objectives and Deliverables: This project...
- Federal Project Grant Award Summary Yale University received a $671,373 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2026, through March 31, 2030. The award funds investigation of ferroptosis regulation in lung inflammation and injury, with research conducted in New Haven, Connecticut. The project extends preliminary studies demonstrating that ciliated cell-specific knockout of the Wnt...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1.46 million Project Grant to The Regents of the University of Colorado (University of Colorado-Denver) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through May 31, 2029. This award funds basic research investigating epimetabolic regulation of macrophage activation in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The research...
- Federal Project Grant Award Summary Florida International University received a $1.37 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 21, 2025, with completion targeted for May 31, 2029. This research award funds a mechanistic investigation into mitochondrial inflammation and sepsis-induced acute lung injury (ALI), with the primary deliverable being peer-reviewed scientific...
Northwestern University received a $1.59M Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 25, 2026, with completion targeted for May 31, 2028. The award funds basic research investigating disordered mitochondrial proteostasis and its role in impairing alveolar epithelial repair in aging lungs. The research seeks to elucidate mechanistic pathways explaining worsened lung injury and delayed recovery from viral pneumonia in elderly populations—a particularly relevant objective given pneumonia's disproportionate lethality among older adults, as underscored during the COVID-19 pandemic. The funded research employs single-cell RNA-sequencing and murine model systems to characterize the relationship between mitochondrial complex I dysfunction, alterations in cellular metabolism (NADH/NAD+ ratios), and pathologic activation of the integrated stress response during alveolar epithelial type 2 (AT2) to type 1 (AT1) cell differentiation. Preliminary findings indicate that loss of mitochondrial complex I function in AT2 cells leads to progressive fatal lung fibrosis, supporting the hypothesis that age-related mitochondrial dysfunction impairs lung recovery mechanisms. The deliverables include research outputs, scientific publications, and mechanistic insights intended to inform future therapeutic interventions targeting age-related lung disease pathology.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.6m | 6/30/26 |